Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Next Previous
Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CMB 305 (Primary) ; CMB 305 (Primary) ; Cyclophosphamide; G 305; Glycopyranosyl lipid adjuvant; LV 305
  • Indications Fallopian tube cancer; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Ovarian cancer; Soft tissue sarcoma; Solid tumours; Synovial sarcoma
  • Focus Adverse reactions; First in man
  • Sponsors Immune Design

Most Recent Events

  • 29 Jun 2020 Status changed from completed to discontinued.
  • 21 May 2019 Status changed from active, no longer recruiting to completed.
  • 12 Mar 2018 Results published in the Immune Design media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top